Table 9.
Outcomes predicted by models for one birth cohort in Amr- region
| POLYMODa | Roxanne | CoRoVa | |
|---|---|---|---|
| Undiscounted cases | |||
| Mild | 8,989 | 11,318 | 12,481 |
| Moderate | 4,760 | 6,471 | 5,286 |
| Severe | 496 | 897 | 514 |
| Nosocomial | 164 | 193 | 263 |
| Deaths | 31 | 59 | 50 |
| Outpatient | 5,256 | 6,471 | 5,286 |
| Inpatient (comm. acq.) | 496 | 897 | 514 |
| Discounted savings | |||
| Outpatient | $181,333 | $216,626 | $239,534 |
| Inpatient | $330,083 | $432,618 | $255,186 |
| Indirect | $105,467 | $98,697 | $78,947 |
| Discounted net costsb (*1000) | $293 | $ 346-1,127 | $ 495-1271 |
| Discounted QALYs | |||
| Mortality | 900 | 1,662 | 1,413 |
| Morbidity | 53 | 66 | 61 |
a. Approximations for one cohort from the multi-cohort results; b. Health-care perspective and range given for previous upper and lower vaccine prices if appropriate